Biomark Diagnostics (STU:20B) Other Current Payables: €0.44 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:20B Biomark Diagnostics Inc STU:20B
27 GF Score
Price €0.32
! 4 Warning Signs
View Full Analysis

What is Biomark Diagnostics Other Current Payables?

Biomark Diagnostics STU:20B 27 Other Current Payables is €0.44 Mil as of Mar. 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Biomark Diagnostics's Other Current Payables for the quarter that ended in Mar. 2026 was €0.44 Mil.

Biomark Diagnostics's quarterly Other Current Payables increased from Sep. 2025 (€0.40 Mil) to Dec. 2025 (€0.42 Mil) and increased from Dec. 2025 (€0.42 Mil) to Mar. 2026 (€0.44 Mil).

Biomark Diagnostics's annual Other Current Payables declined from Mar. 2024 (€0.50 Mil) to Mar. 2025 (€0.43 Mil) but then increased from Mar. 2025 (€0.43 Mil) to Mar. 2026 (€0.44 Mil).

Biomark Diagnostics Other Current Payables Related Terms

Biomark Diagnostics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics Other Current Payables Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.57 0.50 0.43 0.44

Biomark Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.42 0.40 0.42 0.44
STU:20B
27GF Score
Biomark Diagnostics Inc STU:20B
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.44 Mil mean?
Biomark Diagnostics (STU:20B) has a Other Current Payables of €0.44 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' Other Current Payables too high?
Biomark Diagnostics' current Other Current Payables is €0.44 Mil. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Other Current Payables compare to TMO and DHR?
Biomark Diagnostics' Other Current Payables of €0.44 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Diagnostics & Research company?
A good Other Current Payables depends on the Medical Diagnostics & Research industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current Other Current Payables is €0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current Other Current Payables of €0.44 Mil. The current Other Current Payables is €0.44 Mil. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current Other Current Payables is €0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Other Exchanges BMKDF:USABUX:Canada
Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score

Get the complete analysis for STU:20B

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price